United States: Important New FDA Guidance On Postmarketing Approaches To Obtain Data On Under-Represented Populations In Clinical Trials - Foley & Lardner

United States: Important New FDA Guidance On Postmarketing Approaches To Obtain Data On Under-Represented Populations In Clinical Trials - Foley & Lardner

Mondaq

Published

On August 10, 2023, the U.S. Food & Drug Administration (FDA) published new guidance on obtaining data on underrepresented populations in clinical trials after approval of a New Drug Application (NDA)...

Full Article